Related Experiment Video
Updated: Mar 29, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?
Horrick Sharma1, Soumava Santra1, Aloke Dutta1
1Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202, USA.
Abstract:
The current therapy for depression is less than ideal with remission rates of only 25-35% and a slow onset of action with other associated side effects. The persistence of anhedonia originating from depressed dopaminergic activity is one of the most treatment-resistant symptoms of depression. Therefore, it has been hypothesized that triple reuptake inhibitors (TRIs) with potency to block dopamine reuptake in addition to serotonin and norepinephrine transporters should produce higher efficacy. The current review comprehensively describes the development of TRIs and discusses the importance of evaluation of in vivo transporter occupancy of TRIs, which should correlate with efficacy in humans.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Drugs Affecting Neurotransmitter Release or Uptake
G-protein Coupled Receptors
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

